AstraZeneca and Daiichi Sankyo Partner with Summit to Test Datroway Plus Ivonescimab in Phase III TNBC
AZN is trading near its 52-week low of $146.1 (8.8% above the low).
Summary
AstraZeneca and Daiichi Sankyo will collaborate with Summit Therapeutics to test Datroway plus ivonescimab in a Phase III first-line TNBC trial, with each company contributing its own medicine and sharing trial costs.
Key Events · M&A and Partnerships · AZN
-
New Clinical Collaboration with Summit
AstraZeneca and Daiichi Sankyo entered a clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types, beginning with a Phase III trial in first-line TNBC.
-
Cost and Rights Structure
Each company will contribute its respective medicine; trials will be sponsored by AstraZeneca or Daiichi Sankyo, with all three companies sharing trial costs and retaining development and commercial rights to their own medicines.
-
Equity Investment in Summit
AstraZeneca recently announced an equity investment in Summit Therapeutics to help support clinical collaborations evaluating ivonescimab combinations, including this Datroway agreement and a separate Sone-Ve agreement.
-
Ivonescimab Development Context
Ivonescimab is approved for certain NSCLC patients in China, with a BLA under FDA review for EGFR-mutated NSCLC, and is being studied in Phase III trials across multiple solid tumour settings.
Analysis · AZN · Life Sciences
AstraZeneca and Daiichi Sankyo have signed a clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types, starting with a Phase III trial in first-line triple-negative breast cancer. The deal expands AstraZeneca's ADC combination strategy and deepens its relationship with Summit, which also includes a recently announced equity investment. For a company of AstraZeneca's scale, this is a pipeline-building move rather than a near-term financial event, but it signals conviction in ivonescimab as a foundational immunotherapy and positions Datroway for a broader label opportunity.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $158.89 on NYSE in the Life Sciences sector, with a market capitalization of approximately $244.6B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.